GlassScriptPhysician profile
Karim N Jamal
NPI 1982759221
$71,647.75
in general payments reported to CMS, 2019-2025
24 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $180 · 2021: $783 · 2022: $2,183 · 2023: $15K · 2024: $5,735 · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Consulting Fee: $12K · Food and Beverage: $7,932 · Travel and Lodging: $4,695 · Honoraria: $1,390 · Education: $40.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,512.85 |
| Consulting Fee | $12,460.00 |
| Food and Beverage | $7,932.36 |
| Travel and Lodging | $4,694.94 |
| Honoraria | $1,390.00 |
| Education | $40.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23,663.09 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $18,346.50 | 2021-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $7,853.93 | 2019-2025 | Susvimo, Vabysmo |
| Alimera Sciences, INC. | $5,830.82 | 2021-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $5,726.88 | 2019-2024 | Constellation |
| Genentech, INC. | $5,710.12 | 2023 | Susvimo, Vabysmo |
| Regeneron Pharmaceuticals, INC. | $1,504.85 | 2023-2025 | Eylea |
| Apellis Pharmaceuticals, INC. | $835.31 | 2023-2025 | Syfovre |
| Ocular Therapeutix, INC. | $300.00 | 2024-2025 | Dextenza |
| Notal Vision, INC. | $282.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $278.28 | 2019-2021 | |
| Dutch Ophthalmic, USA | $233.48 | 2019 | |
| Bausch & Lomb Americas INC. | $210.29 | 2022-2025 | Xipere, Visudyne, Retisert |
| Biogen, INC. | $180.90 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.35 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Ani Pharmaceuticals, INC. | $108.45 | 2025 | Iluvien, Yutiq |
| Abbvie INC. | $91.51 | 2022-2025 | |
| Harrow Eye, LLC | $77.74 | 2024-2025 | Iheezo, Triesence |
| Coherus Oncology, INC. | $36.73 | 2023 | |
| Allergan, INC. | $25.02 | 2020-2021 | |
| Sandoz INC. | $20.60 | 2024 | Cimerli |
| Eyepoint US, INC. | $16.28 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Jamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.